Start now

Shop / BPC-157

BPC-157

Repair peptide — we do not dispense this

You will be offered BPC-157 somewhere else, so it is worth being clear about what is actually known.

Nearly all of the published work is in animals. FDA placed it in Category 2 of the 503A bulk substances review — substances with significant safety risks — and although an advisory committee voted 8–6 in July 2026 to recommend listing it, that vote is advisory and HHS has not acted on it.

We would rather lose the sale than put a needle in your arm on the strength of rat studies. If real human evidence arrives, this page changes and we will say so here.

Preclinical only

Almost all published data is from animal or laboratory work. No completed human efficacy trial has been published.

Cat. 2

FDA placed BPC-157 in 503A Category 2 — bulk substances with significant safety risks

FDA, 2023
8–6

Advisory committee vote recommending it for the 503A bulks list, 23–24 July 2026

PCAC — advisory only
None

Completed published randomised controlled trials of efficacy in humans

As of August 2026

What it is

BPC-157 is a synthetic 15–amino-acid peptide derived from a protein sequence found in human gastric juice. It is widely sold and widely discussed as a soft-tissue repair compound. <strong>Whealth does not dispense it.</strong> This page exists because you will be offered it elsewhere and you should know what the evidence actually is.

How it works

In animal models it appears to promote angiogenesis and accelerate healing in tendon, ligament, muscle and gut tissue, with proposed effects on the nitric-oxide system and on growth-factor signalling. Every part of that sentence describes work done in rats.

What the evidence actually says

  1. 2018

    Preclinical review

    A review of BPC-157 alongside standard angiogenic growth factors, covering healing in gastrointestinal tract, tendon, ligament and muscle. Substantial, careful work — and almost entirely in animals.

  2. 2023

    Category 2

    FDA placed BPC-157 in Category 2 of the 503A bulk substances review: substances with significant safety risks, which compounders may not use.

  3. 2026

    PCAC vote

    On 23–24 July the Pharmacy Compounding Advisory Committee voted 8–6 to recommend BPC-157 for the 503A bulks list, and backed five other peptides. The vote is advisory. HHS has not acted on it, and the recommendation is publicly contested.

What the first months look like

  • TodayNothing. We do not prescribe or dispense BPC-157, and no physician working with us will write it.
  • If HHS actsA 503A listing would make it legally compoundable. It would not create the human efficacy evidence, and we would still want that before selling it.

Who this is not for

  • Anyone, from us, at present.
  • If you are buying it elsewhere, know that research-use-only material is not manufactured to pharmaceutical standard, is not tested for sterility or endotoxin, and is not what a 503A pharmacy would dispense.
Sources
  1. Seiwerth S et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des 2018;24(18):1972–1989. PMID 29998800.
  2. FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A.

Figures are quoted from the published trials and were last checked in August 2026. We update this page when the evidence changes.